Emmanuel Aris

990 total citations
48 papers, 701 citations indexed

About

Emmanuel Aris is a scholar working on Epidemiology, Microbiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Emmanuel Aris has authored 48 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Epidemiology, 18 papers in Microbiology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Emmanuel Aris's work include Pneumonia and Respiratory Infections (19 papers), Bacterial Infections and Vaccines (18 papers) and Influenza Virus Research Studies (11 papers). Emmanuel Aris is often cited by papers focused on Pneumonia and Respiratory Infections (19 papers), Bacterial Infections and Vaccines (18 papers) and Influenza Virus Research Studies (11 papers). Emmanuel Aris collaborates with scholars based in Belgium, United States and United Kingdom. Emmanuel Aris's co-authors include Jeanne‐Marie Devaster, Simon Bourne, Tom Wilkinson, Stuart C. Clarke, Andrew Tuck, Karl J. Staples, Kristoffer Ostridge, Nicholas Williams, Stephen A. Wootton and Viktoriya Kim and has published in prestigious journals such as SHILAP Revista de lepidopterología, PEDIATRICS and The Journal of Infectious Diseases.

In The Last Decade

Emmanuel Aris

43 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emmanuel Aris Belgium	16	428	258	237	101	90	48	701
Roberta Droghetti Italy	11	419 1.0×	167 0.6×	133 0.6×	87 0.9×	67 0.7×	12	562
J. Rüggeberg United Kingdom	9	493 1.2×	84 0.3×	191 0.8×	37 0.4×	75 0.8×	13	734
Anne Balloch Australia	19	536 1.3×	80 0.3×	204 0.9×	46 0.5×	77 0.9×	45	883
Pekka Honkanen Finland	13	548 1.3×	102 0.4×	90 0.4×	16 0.2×	118 1.3×	28	695
Joyce K. Lammert United States	5	208 0.5×	168 0.7×	36 0.2×	150 1.5×	156 1.7×	7	446
Manika Suryadevara United States	15	413 1.0×	92 0.4×	62 0.3×	16 0.2×	242 2.7×	44	612
Sarah S. Long United States	12	835 2.0×	204 0.8×	141 0.6×	12 0.1×	107 1.2×	22	1.0k
Jolice P. van den Berg Netherlands	9	181 0.4×	89 0.3×	44 0.2×	23 0.2×	46 0.5×	9	436
Elena Tremolati Italy	13	406 0.9×	102 0.4×	35 0.1×	31 0.3×	94 1.0×	14	539
Robert T. Chen United States	7	559 1.3×	43 0.2×	84 0.4×	107 1.1×	381 4.2×	8	884

Countries citing papers authored by Emmanuel Aris

Since Specialization

Citations

This map shows the geographic impact of Emmanuel Aris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuel Aris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuel Aris more than expected).

Fields of papers citing papers by Emmanuel Aris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuel Aris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuel Aris. The network helps show where Emmanuel Aris may publish in the future.

Co-authorship network of co-authors of Emmanuel Aris

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuel Aris. A scholar is included among the top collaborators of Emmanuel Aris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuel Aris. Emmanuel Aris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Constenla, Dagna, et al.. (2025). Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases. The Journal of Infectious Diseases. 232(6). e931–e940. 1 indexed citations

Constenla, Dagna, et al.. (2024). P986 Effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) among patients ≥50 years of age with Inflammatory Bowel Disease in the United States: A retrospective real-world database analysis from 2018 to 2021. Journal of Crohn s and Colitis. 18(Supplement_1). i1779–i1780.

Aris, Emmanuel, et al.. (2024). Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis. BMC Public Health. 24(1). 2960–2960. 3 indexed citations

Callegaro, Andrea, Naveen Karkada, Emmanuel Aris, & Toufik Zahaf. (2023). Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies. Pharmaceutical Statistics. 22(3). 475–491. 3 indexed citations

Aris, Emmanuel, Amit Bhavsar, Jason C. Simeone, et al.. (2023). Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England. Infectious Diseases and Therapy. 12(4). 1103–1118. 9 indexed citations

Bhavsar, Amit, Emmanuel Aris, Jason C. Simeone, et al.. (2022). Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England. SHILAP Revista de lepidopterología. 14 indexed citations

Hogea, Cosmina, et al.. (2022). POSB60 Evolution of Direct Medical Costs Associated with Respiratory Syncytial Virus Disease in Older Adults: A Retrospective Database Analysis from 2008 to 2017. Value in Health. 25(1). S71–S72. 2 indexed citations

Shen, Jing, S. Bouée, Emmanuel Aris, Corinne Emery, & Ekkehard Beck. (2021). Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease—Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Infectious Diseases and Therapy. 11(1). 249–262. 19 indexed citations

Borja-Tabora, Charissa, Paula Peyrani, Chris Webber, et al.. (2020). A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases. 20(1). 426–426. 10 indexed citations

10.

Aris, Emmanuel, Marion Montourcy, Elizabeth Esterberg, et al.. (2020). The adult vaccination landscape in the United States during the Affordable Care Act era: Results from a large retrospective database analysis. Vaccine. 38(14). 2984–2994. 15 indexed citations

11.

Williams, Nicholas, Kristoffer Ostridge, Jeanne‐Marie Devaster, et al.. (2018). Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD. Respiratory Research. 19(1). 143–143. 24 indexed citations

12.

Ostridge, Kristoffer, Nicholas Williams, Viktoriya Kim, et al.. (2018). Relationship of CT-quantified emphysema, small airways disease and bronchial wall dimensions with physiological, inflammatory and infective measures in COPD. Respiratory Research. 19(1). 31–31. 29 indexed citations

13.

Coombs, Ngaire, Karl J. Staples, Kristoffer Ostridge, et al.. (2017). Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. European Respiratory Journal. 50(4). 1700853–1700853. 64 indexed citations

14.

Kurosky, Samantha K., et al.. (2017). Inter-State Variability Of Adult Vaccination Coverage In The United States: Can We Explain It?. Value in Health. 20(9). A799–A799. 1 indexed citations

15.

Wilkinson, Tom, Emmanuel Aris, Simon Bourne, et al.. (2017). A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 72(10). 919–927. 139 indexed citations

16.

Leroux‐Roels, Geert, Pierre Van Damme, Wouter Haazen, et al.. (2016). Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. 34(27). 3156–3163. 27 indexed citations

17.

Bryant, Kristina A., Terry Nolan, Noris Pavía-Ruz, et al.. (2012). The safety profile ofHaemophilus influenzaetype b–Neisseria meningitidisserogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Human Vaccines & Immunotherapeutics. 8(3). 304–311. 9 indexed citations

18.

Bryant, Kristina A., Gary S. Marshall, Colin D. Marchant, et al.. (2011). Immunogenicity and Safety of H influenzae Type b–N meningitidis C/Y Conjugate Vaccine in Infants. PEDIATRICS. 127(6). e1375–e1385. 24 indexed citations

19.

Nolan, Terry, Peter Richmond, Helen Marshall, et al.. (2010). Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine. The Pediatric Infectious Disease Journal. 30(3). 190–196. 21 indexed citations

20.

Marshall, Gary S., Colin D. Marchant, Mark M. Blatter, et al.. (2010). IMMUNE RESPONSE AND ONE-YEAR ANTIBODY PERSISTENCE AFTER A FOURTH DOSE OF A NOVEL HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS SEROGROUPS C AND Y-TETANUS TOXOID CONJUGATE VACCINE (HibMenCY) AT 12 TO 15 MONTHS OF AGE. The Pediatric Infectious Disease Journal. 29(5). 469–471. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact